09:13 AM EST, 11/05/2025 (MT Newswires) -- Viridian Therapeutics ( VRDN ) reported a Q3 net loss Wednesday of $0.34 per share, narrowing from a loss of $0.88 a year earlier.
Four analysts polled by FactSet expected a loss of $1.16.
Total revenue for the quarter ended Sept. 30 was $70.6 million, compared with $86,000 a year earlier.
Analysts' estimates weren't available for comparison.
Shares of the company were up 5.9% in recent Wednesday premarket activity.